JP6500105B2 - ペプチドが結合された安定したアスコルビン酸誘導体、その製造方法、及びそれを含む化粧料組成物 - Google Patents

ペプチドが結合された安定したアスコルビン酸誘導体、その製造方法、及びそれを含む化粧料組成物 Download PDF

Info

Publication number
JP6500105B2
JP6500105B2 JP2017527922A JP2017527922A JP6500105B2 JP 6500105 B2 JP6500105 B2 JP 6500105B2 JP 2017527922 A JP2017527922 A JP 2017527922A JP 2017527922 A JP2017527922 A JP 2017527922A JP 6500105 B2 JP6500105 B2 JP 6500105B2
Authority
JP
Japan
Prior art keywords
peptide
ascorbic acid
amino
bound
acid derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017527922A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018509376A5 (cg-RX-API-DMAC7.html
JP2018509376A (ja
Inventor
ヨン ジュン パク
ヨン ジュン パク
ジュン ユン キム
ジュン ユン キム
ジン キョ ジョン
ジン キョ ジョン
ヒョン ミ キム
ヒョン ミ キム
ユン チュ チョウ
ユン チュ チョウ
チュ ヒュク イム
チュ ヒュク イム
ヒュン ナム ソン
ヒュン ナム ソン
ソン キュン パク
ソン キュン パク
ウォン カン ムン
ウォン カン ムン
シン ジェ チャン
シン ジェ チャン
スン ソ ホン
スン ソ ホン
Original Assignee
セルトリオン・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セルトリオン・インコーポレイテッド filed Critical セルトリオン・インコーポレイテッド
Publication of JP2018509376A publication Critical patent/JP2018509376A/ja
Publication of JP2018509376A5 publication Critical patent/JP2018509376A5/ja
Application granted granted Critical
Publication of JP6500105B2 publication Critical patent/JP6500105B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C07F9/65846Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a six-membered ring which may be condensed with another ring system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/676Ascorbic acid, i.e. vitamin C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/02Preparations for care of the skin for chemically bleaching or whitening the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/62Three oxygen atoms, e.g. ascorbic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0815Tripeptides with the first amino acid being basic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0815Tripeptides with the first amino acid being basic
    • C07K5/0817Tripeptides with the first amino acid being basic the first amino acid being Arg
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C07H11/04Phosphates; Phosphites; Polyphosphates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017527922A 2014-11-27 2015-10-22 ペプチドが結合された安定したアスコルビン酸誘導体、その製造方法、及びそれを含む化粧料組成物 Active JP6500105B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2014-0167350 2014-11-27
KR20140167350 2014-11-27
PCT/KR2015/011218 WO2016085127A2 (ko) 2014-11-27 2015-10-22 펩타이드가 결합된 안정한 아스코르빈산 유도체, 그의 제조방법 및 그를 포함하는 화장료 조성물

Publications (3)

Publication Number Publication Date
JP2018509376A JP2018509376A (ja) 2018-04-05
JP2018509376A5 JP2018509376A5 (cg-RX-API-DMAC7.html) 2018-11-15
JP6500105B2 true JP6500105B2 (ja) 2019-04-10

Family

ID=56075108

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017527922A Active JP6500105B2 (ja) 2014-11-27 2015-10-22 ペプチドが結合された安定したアスコルビン酸誘導体、その製造方法、及びそれを含む化粧料組成物

Country Status (8)

Country Link
US (1) US10239902B2 (cg-RX-API-DMAC7.html)
EP (1) EP3225620B1 (cg-RX-API-DMAC7.html)
JP (1) JP6500105B2 (cg-RX-API-DMAC7.html)
KR (1) KR101652204B1 (cg-RX-API-DMAC7.html)
CN (1) CN107207566B (cg-RX-API-DMAC7.html)
ES (1) ES2767412T3 (cg-RX-API-DMAC7.html)
SG (1) SG11201704321TA (cg-RX-API-DMAC7.html)
WO (1) WO2016085127A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018005762A2 (en) * 2016-06-29 2018-01-04 Orasis Medical, Inc. Ascorbic acid-amino acid conjugates and their use in regulation of fluid outflow
JP6875704B2 (ja) * 2018-04-13 2021-05-26 マイクロアルジェコーポレーション株式会社 メラニン生成抑制用組成物、美白用組成物、及び発現抑制用組成物
KR102130701B1 (ko) * 2018-09-27 2020-07-06 주식회사 차메디텍 비타민 c가 결합된 펩타이드 유도체 및 이를 포함하는 조성물
KR102222697B1 (ko) 2019-05-02 2021-03-04 (주)리즈케이 아스코르빈산 함유 화장료 조성물 및 이를 포함하는 화장품
KR102740870B1 (ko) * 2020-08-05 2024-12-12 주식회사 레미바이오 아스코르브산 유도체 및 이를 포함하는 조성물
CN115260170B (zh) * 2021-04-30 2024-05-28 禾美生物科技(浙江)有限公司 抗坏血酸多肽衍生物及其制备方法和应用
KR102726678B1 (ko) 2022-04-20 2024-11-07 주식회사 바른바름 4-알킬레졸시놀을 포함하는 고체지질 나노입자, 이를 포함하는 화장료 조성물 및 화장품
KR102576447B1 (ko) * 2022-11-14 2023-09-08 주식회사 차메디텍 열 안정성이 증대된 비타민 c-펩타이드 유도체 및 이를 포함하는 콜라겐 형성용, 미백용 및/또는 항산화용 조성물
CN116035923B (zh) * 2022-11-19 2024-12-20 陕西佰鸿合成生物科技有限公司 一种含神经酰胺&rgd多肽的纳米乳液及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5409693A (en) * 1989-10-12 1995-04-25 Perricone; Nicholas V. Method for treating and preventing sunburn and sunburn damage to the skin
JP2772712B2 (ja) * 1990-11-15 1998-07-09 花王株式会社 アスコルビン酸誘導体及びその製造法
US5714484A (en) * 1993-12-08 1998-02-03 Prototek, Inc. α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors
FR2764891B1 (fr) * 1997-06-04 2001-04-13 Pacific Corp Derive de l'acide l-ascorbique stable dans l'eau, procede pour sa preparation et composition cosmetique de blanchiment de la peau le contenant
JP2001270816A (ja) * 2000-03-23 2001-10-02 Ichimaru Pharcos Co Ltd 化粧料組成物
EP1365813A4 (en) * 2001-02-26 2006-03-22 Bristol Myers Squibb Pharma Co ASCORBIC ACID ANALOGUES FOR METALLORADIOPHARMACEUTICAL PRODUCTS
AU2002332244A1 (en) * 2002-09-24 2004-04-19 Akita Prefecture Demelanizing agents, beautifying agents, demelanizing compositions and beautifying compositions
KR100459679B1 (ko) * 2003-04-30 2004-12-03 주식회사 펩트론 펩타이드가 결합된 비타민 씨 유도체, 이의 제조방법 및이를 포함하는 조성물
WO2007094030A1 (ja) * 2006-02-13 2007-08-23 Sakamoto Bio Co., Ltd. 美白剤
KR100691540B1 (ko) * 2006-06-22 2007-03-12 주식회사 펩트론 펩타이드가 결합된 안정화된 비타민 c 유도체, 이의제조방법 및 이를 함유하는 조성물
JP5255775B2 (ja) * 2007-03-15 2013-08-07 ピアス株式会社 水性ゲル、皮膚外用剤および化粧料
KR101413939B1 (ko) * 2007-10-20 2014-06-30 재단법인서울대학교산학협력재단 펩타이드가 결합된 아스코르빈산 유도체
US9408797B2 (en) * 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment

Also Published As

Publication number Publication date
KR20160063976A (ko) 2016-06-07
EP3225620A4 (en) 2018-11-07
WO2016085127A2 (ko) 2016-06-02
CN107207566A (zh) 2017-09-26
EP3225620A2 (en) 2017-10-04
CN107207566B (zh) 2021-01-22
KR101652204B1 (ko) 2016-08-29
SG11201704321TA (en) 2017-06-29
US10239902B2 (en) 2019-03-26
WO2016085127A3 (ko) 2016-10-06
ES2767412T3 (es) 2020-06-17
EP3225620B1 (en) 2019-11-20
JP2018509376A (ja) 2018-04-05
US20170258931A1 (en) 2017-09-14

Similar Documents

Publication Publication Date Title
JP6500105B2 (ja) ペプチドが結合された安定したアスコルビン酸誘導体、その製造方法、及びそれを含む化粧料組成物
AU2007317045B2 (en) Michael systems as transglutaminase inhibitors
JP2018509376A5 (cg-RX-API-DMAC7.html)
CA2703491A1 (en) Tubulysins and processes for preparing
JPS58116443A (ja) 新規ペプチドおよびその製法
JP6801835B2 (ja) β−ターンペプチド模倣環状塩の液相合成及び結晶化
CN111269137A (zh) 一种液相法制备索马鲁肽侧链的方法
Coin et al. The depsipeptide technique applied to peptide segment condensation: Scope and limitations
EP4574834A1 (en) Method for synthesizing amide and/or polypeptide with unprotected amino acid as amine component
JP5947821B2 (ja) セレウリドおよびその誘導体の製造方法、セレウリド製造の為の中間体ならびにセレウリド誘導体
HK1237798A1 (en) Stable peptide-conjugated ascorbic acid derivative, method for preparing same, and cosmetic composition containing same
JP2020529472A (ja) ペプチド化合物の環化放出関連する出願の相互参照
WO2022149584A1 (ja) ペプチド
HK1237798B (zh) 稳定的肽缀合抗坏血酸衍生物、用於制备其的方法和包含其的化妆品组合物
Pohlmann et al. Synthesis and conformational analysis of two 2‐oxopiperazine‐containing tetrapeptide analogues
JP2008247806A (ja) Pf1022類の製造法
US9605020B2 (en) Method for producing dipeptide derivative containing disubstituted amino acid residue
KR101969345B1 (ko) 펩타이드가 결합된 안정한 아스코르빈산 유도체를 포함하는 피부 염증 완화용 조성물
US20260008808A1 (en) Method for Synthesizing Amide and/or Polypeptide Using Unprotected Amino Acid as Ammonia Component
Rodrigues et al. Synthesis and conformational investigation of tetrapeptide analogues of the fragment B23-B26 of insulin
Hättasch et al. Triazole groups as biomimetic amide groups in peptides can trigger racemization.
JPH01246257A (ja) 3―チオプロピオン酸誘導体の製造法
Rakofsky Metal Carboxylate Salts as an Avenue to Protecting Group Free Peptide Couplings
WO2016193709A1 (en) Synthesis of duocarmycin analogues
US3585180A (en) Process for preparing peptides containing histidine protected with a 2,2,2,-trihalogeno - n -benzyloxycarbonylaminoethyl group

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180709

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20181002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190311

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190318

R150 Certificate of patent or registration of utility model

Ref document number: 6500105

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250